Senzime wins US deal for 50 TetraGraph systems

Press release: Uppsala February 17, 2022. Senzime announces today that the company has won an order from a large American university hospital regarding the placement of 50 TetraGraph systems and with associated disposable sensors to an estimated value of SEK 1.5 million annually.

This order is a broad deployment of TetraGraph systems across all the hospital's operating rooms, which includes 50 systems with associated disposable sensors. Senzime estimates that the Lifetime Value (LTV) of a delivered TetraGraph, including the use of TetraSens sensors, amounts to 250 TSEK over 5 years with a gross margin exceeding 65 percent.

According to the company's own calculations, this corresponds to an initial annual sale of SEK 1.5 million with the potential to reach an annual sale of SEK 3 million when all systems are implemented.

Senzime's American subsidiary, Senzime Inc, has gradually expanded and today consists of thirteen people, ten of whom work directly with sales and the others combine sales with clinical support and management.

“It is fantastic that the hospital chooses to equip all operating rooms with TetraGraph. By introducing monitoring as a standard for all patients receiving muscle relaxants, patient safety is increased, and the risk of complications is dramatically reduced”, says Pia Renaudin, CEO of Senzime

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops and markets CE- and FDA-cleared monitoring systems for patients undergoing anesthesia. Senzime’s employees worldwide are committed to the vision of a world without anesthesia related complications. Six out of ten patients that wake up after surgery are not fully muscle recovered and therefor at risk having critical respiratory complications. The TetraGraph system helps anesthesia providers improve patient care and reduce healthcare costs by digitally and continuously measure the degree of neuromuscular blockade under and after surgery. Senzime operates in the worlds leading markets targeting a market opportunity valued in excess of SEK 15 billion per year. The company’s shares are listed on Nasdaq Stockholms main market (ticker SEZI). www.senzime.com

Attachments

Senzime wins US deal for 50 TetraGraph systems

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.

Contact us now